Autopsy report · NCT04354428

Treatment for COVID-19 in High-Risk Adult Outpatients

“Low number of events contributing to primary outcome”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 7 months before it stopped.
• 289 participants enrolled.
• Results were posted on the registry 1 year 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

University of Washington

Sponsor type

University, hospital or other

Conditions

COVID-19; SARS-CoV-2

Interventions

Ascorbic Acid; Hydroxychloroquine Sulfate; Azithromycin; Folic Acid; Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]

Participants

289

Sites

6

Countries

United States

Trials that died the same way

• BLeeding Events and Maintenance DoSe of PraSugrel
  “Low events rate. Scarce economical resources” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.